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ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin type 1 motifs 13), 
also known as "von Willebrand factor (VWF) cleaving protease" is responsible for 
modulating the size of VWF multimers in the circulation.  Acquired or congenital deficiency 
of ADAMTS13 is associated with the circulation of ultra-large multimers of VWF which can 
lead to thrombotic thrombocytopoenic purpura (TTP) characterised by disseminated platelet 
aggregation and thrombosis in the microcirculation, severe platelet deficiency, red cell 
haemolysis and organ damage [1,2].  Measurement of ADAMTS13 activity in plasma is an 
important component in the diagnosis and treatment of TTP and numerous methods, both 
commercial and "in house", are available for the estimation of ADAMTS13 activity and 
antigen [3].  However, there is currently no internationally accepted unitage to support 
harmonisation of measurement between laboratories hence the development of the World 
Health Organisation 1st International Standard (WHO IS) for ADAMTS13 in plasma.  The 
candidate WHO IS (coded 12/252) was prepared from a pool of 38 donations from normal 
healthy donors and 1 ml aliquots were dispensed into approximately 10,000 glass ampoules 
prior to freeze-drying and sealing. 
A collaborative study involving 32 laboratories from 14 countries was undertaken to assign 
values for activity and antigen to the candidate WHO IS based on assays relative to local 
pooled normal plasma preparations.  The candidate WHO IS was included in the study as 
coded duplicates (samples A & B).  Most laboratories used VWF A2 domain peptide 
substrate assays either in a Fluorescence Resonance Energy Transfer (FRET) assay (n=18) or 
an activity ELISA (n=9) to measure ADAMTS13 activity and all laboratories used ELISA for 
antigen measurement.  Comparison of the candidate WHO IS with the local normal pools was 
associated with a high degree of validity in terms of parallelism of the dose-response 
relationships with only 9/117 activity assays and 8/58 antigen assays excluded because of 
non-parallelism.  There was no significant difference between the coded duplicates of the 
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candidate WHO IS for estimates of activity or antigen nor between estimates of activity using 
the FRET and the activity ELISA methods.  Combination of all results for activity gave an 
overall mean of 0.91 units/ml for the candidate WHO IS with inter-laboratory variability 
(geometric coefficient of variation, GCV) of 12.4%.  For estimates of ADAMTS13 antigen 
the combination of all results gave an overall mean of 0.92 units/ml with inter-laboratory 
variability (GCV) of 16.3%. 
Two plasma exchange waste bag samples (coded C & D) from a patient with acquired 
ADAMTS13 deficiency due to an inhibitory autoantibody, treated with plasma exchange, 
were also included in the study.  The level of ADAMTS13 in sample C was below the limit 
of detection for assays of activity in many cases (21/32) and calculated estimates were only 
possible in 11 laboratories.  However, 31/32 results were consistent with a severe deficiency 
below 0.1 units/ml.  Patient sample D contained a higher level of ADAMTS13 and 24/32 data 
sets from the activity assays could be quantified.  The overall mean estimate for activity in 
sample D was 0.15 units/ml with 23/24 laboratories agreeing levels below 0.3 units/ml 
whereas the mean estimate for antigen was higher at 0.63 units/ml (Fig 1).  Estimates of both 
activity and antigen in sample D, calculated relative to the local pools, were associated with 
large inter-laboratory variability (GCVs 54% and 46% respectively) and there was little or no 
improvement when estimates were calculated relative to the proposed WHO IS (GCVs 63% 
and 32% respectively).  This indicates that the large inter-laboratory variability is not 
primarily caused by the use of different local plasma pools but may also include 
methodological differences between laboratories as previously suggested in reports from 
other multi-centre studies, particularly when assaying samples with acquired ADAMTS13 
deficiency [4,5,6].  The availability of a common reference material (WHO IS) should 
facilitate future work to identify the causes of inter-laboratory variability.  Ratios of mean 
activity to antigen for patient samples C and D were greatly reduced at 0.11 and 0.24 
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respectively compared to normal plasma (0.99).  This finding is probably related to the 
presence of circulating ADAMTS13-antibody complexes where ADAMTS13 activity is 
inhibited but which can still be detected by assays for antigen [7].  Assays of recombinant 
ADAMTS13 (sample E) indicated valid comparison of dose-response relationships with 
normal plasma (proposed WHO IS) but large inter-laboratory variability of estimates for both 
activity (GCV 45%) and antigen (GCV 72%).  This variability could reflect the high dilution 
factors required for the assay of the recombinant sample or indicate that the proposed WHO 
IS is not optimal for measuring recombinant ADAMTS13. 
The proposal to assign the consensus mean values for ADAMTS13 activity (0.91 IU per 
ampoule) and antigen (0.92 IU per ampoule) to the WHO 1st IS ADAMTS13 Plasma 
(12/252) was endorsed by the Expert Committee on Biological Standardisation of WHO in 
October 2014 [8]. 
 
Addendum 
A Hubbard and J Kremer Hovinga were responsible for preparing the test samples and  
managing the multi-centre collaborative study.  Statistical analysis and assay design were  
provided by A Heath.  
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Figure 1 Mean laboratory estimates for ADAMTS13 activity and antigen in patient 
plasma (sample D) relative to the local normal plasma pools (L) and the WHO 
1st IS ADAMTS13 Plasma (12/252) (IS).  Laboratory estimates below the 
level of quantification are plotted as zero  
 
 
 
 
